YU41902A - Kombinacija inhibitora resorpcije serotonina i 5-ht2c antagonista, inverznog agonista ili delimičnog agonista - Google Patents

Kombinacija inhibitora resorpcije serotonina i 5-ht2c antagonista, inverznog agonista ili delimičnog agonista

Info

Publication number
YU41902A
YU41902A YU41902A YUP41902A YU41902A YU 41902 A YU41902 A YU 41902A YU 41902 A YU41902 A YU 41902A YU P41902 A YUP41902 A YU P41902A YU 41902 A YU41902 A YU 41902A
Authority
YU
Yugoslavia
Prior art keywords
serotonin reuptake
agonist
combination
reuptake inhibitor
inverse
Prior art date
Application number
YU41902A
Other languages
English (en)
Inventor
Thomas Ivo F. Hubert Cremers
Hakan Wilhelm Wikstrom
Johan Antonie Den Boer
Fokko Jan Bosker
Bernard H. Cornelius Westerink
Klaus Peter Bogeso
Sandra Hogg
Arne Mork
Original Assignee
H. Lundbeck A/S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S. filed Critical H. Lundbeck A/S.
Publication of YU41902A publication Critical patent/YU41902A/sh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9413—Dopamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)

Abstract

Ovaj pronalazak odnosi se na upotrebu jedinjenja i kompozicije jedinjenja koja imaju inhibirajuću aktivnost resorbcije serotonina i 5-HT2C antagonističnu, delimično agonističnu ili inverzno agonističnu aktivnos za lečenje depresije i drugih afektivnih bolesti. Kombinovano inhibirajuće dejstvo resorbcije serotonina i 5-HT2C antagonistično, deliminčno agonistično ili inverzno agonistično dejstvo može se nalaziti u okviru istog hemijskog jedinjenja ili u dva različita hemijska jedinjenja.[The present invention relates to the use of compounds and compositions of compounds having serotonin reuptake inhibiting activity and 5-HT2C antagonistic, partial agonistic or inverse agonistic activity for the for the treatment of depression and other affective disorders. The combined serotonin reuptake inhibiting effect and the 5-HT2C antagonistic, partial agonistic or inverse agonistic effect may reside within the same chemical compound or in two different chemical compounds.
YU41902A 1999-12-06 2000-12-06 Kombinacija inhibitora resorpcije serotonina i 5-ht2c antagonista, inverznog agonista ili delimičnog agonista YU41902A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16924599P 1999-12-06 1999-12-06

Publications (1)

Publication Number Publication Date
YU41902A true YU41902A (sh) 2005-06-10

Family

ID=22614803

Family Applications (1)

Application Number Title Priority Date Filing Date
YU41902A YU41902A (sh) 1999-12-06 2000-12-06 Kombinacija inhibitora resorpcije serotonina i 5-ht2c antagonista, inverznog agonista ili delimičnog agonista

Country Status (33)

Country Link
US (4) US20020103249A1 (sh)
EP (2) EP2036564A1 (sh)
JP (1) JP2003516326A (sh)
KR (1) KR100832026B1 (sh)
CN (2) CN101406465A (sh)
AT (1) ATE314849T1 (sh)
AU (2) AU1850801A (sh)
BG (1) BG106895A (sh)
BR (1) BR0016385A (sh)
CA (1) CA2393470A1 (sh)
CO (1) CO5251409A1 (sh)
CY (1) CY1105014T1 (sh)
CZ (1) CZ20021961A3 (sh)
DE (1) DE60025398T2 (sh)
DK (1) DK1237553T3 (sh)
EA (1) EA006391B1 (sh)
ES (1) ES2255519T3 (sh)
HR (1) HRP20020527A2 (sh)
HU (1) HUP0203586A3 (sh)
IL (2) IL149994A0 (sh)
IS (1) IS2227B (sh)
ME (1) MEP6208A (sh)
MX (1) MXPA02005613A (sh)
NO (1) NO20022657L (sh)
NZ (1) NZ545907A (sh)
PL (1) PL356402A1 (sh)
PT (1) PT1237553E (sh)
SK (1) SK7962002A3 (sh)
TR (1) TR200201512T2 (sh)
UA (1) UA77650C2 (sh)
WO (2) WO2001041766A1 (sh)
YU (1) YU41902A (sh)
ZA (1) ZA200204391B (sh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
US6589996B2 (en) 2000-03-17 2003-07-08 Orion Corporation Treatment of disorders relating to the serotonergic system
FI20002612A0 (fi) * 2000-11-28 2000-11-28 Orion Yhtymae Oyj Yhdistelmäterapia serotoniinivälityksen häiriöiden hoitamiseksi
AU2002218338A1 (en) * 2000-11-28 2002-06-11 Orion Corporation Treatment of psychiatric disorders with trimethyl-bicyclo(2.2.1)heptane derivatives
US6335372B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Treatment of obsessive compulsive disorder
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
GB0118892D0 (en) * 2001-08-02 2001-09-26 Vernalis Res Ltd Method of treatment
SE0201544D0 (sv) * 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
MXPA05012493A (es) * 2003-05-27 2006-05-25 Forest Laboratories Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
EP1500391A1 (en) * 2003-07-24 2005-01-26 Neuro3D Therapeutic use of bicycloheptane derivatives
DE602004019118D1 (de) 2003-09-17 2009-03-05 Janssen Pharmaceutica Nv Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
WO2005053796A1 (en) * 2003-12-02 2005-06-16 B & B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050241110A1 (en) * 2004-04-09 2005-11-03 Bruce Baker Ergonomic handles, especially for garden tools
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
JP2009538117A (ja) * 2006-03-22 2009-11-05 ハー・ルンドベック・アクチエゼルスカベット うつ病を処置するための化合物を同定する方法
KR101627901B1 (ko) 2006-06-16 2016-06-13 하. 룬트벡 아크티에 셀스카브 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
HUE036004T2 (hu) * 2007-08-03 2018-06-28 Richter Gedeon Nyrt Dopamin receptor ligandumokat tartalmazó gyógyszerkészítmények és kezelési eljárások dopamin receptor ligandumok alkalmazásával
JP2011507835A (ja) 2007-12-21 2011-03-10 アンドレイ・アレクサンドロビッチ・イワシェンコ α−アドレナリン受容体、ドーパミン、ヒスタミン、イミダゾリン及びセロトニン受容体のリガンド並びにその使用
WO2010006231A1 (en) * 2008-07-10 2010-01-14 Ore Pharmaceuticals Inc. Treating inflammation and related conditions with irindalone
US8569353B2 (en) 2010-07-15 2013-10-29 Dainippon Sumitomo Pharma Co., Ltd. Pyrazole compound
EP2629615B1 (en) 2010-10-22 2018-10-10 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
WO2014046544A1 (en) 2012-09-21 2014-03-27 Aapa B.V. Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
WO2016205631A1 (en) * 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders
CN107556206A (zh) * 2016-06-30 2018-01-09 陕西合成药业股份有限公司 一种新型5‑羟色胺再摄取抑制剂类化合物及其制备方法和在医学上的应用
US11478467B2 (en) 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
CN119470729B (zh) * 2025-01-15 2025-04-29 山东英盛生物技术有限公司 一种高效液相色谱-串联质谱法定量检测微量血液中霉酚酸的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5155218A (en) * 1990-05-08 1992-10-13 Neurogenetic Corporation Dna encoding human 5-ht1d receptors
NZ254785A (en) 1992-08-20 1995-09-26 Smithkline Beecham Plc Heterocyclically-condensed indoles and medicaments
WO1994014801A1 (en) 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
AU670675B2 (en) * 1993-02-10 1996-07-25 Yamanouchi Pharmaceutical Co., Ltd. Morpholine derivative
GB9313913D0 (en) 1993-07-06 1993-08-18 Smithkline Beecham Plc Novel compounds
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
WO1996023769A2 (en) 1995-02-02 1996-08-08 Smithkline Beecham Plc Heterocyclic compounds possessing 5ht2c receptor antagonist activity
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
GB9511355D0 (en) 1995-06-06 1995-08-02 Fujisawa Pharmaceutical Co Urea derivatives
GB9514384D0 (en) * 1995-07-13 1995-09-13 American Home Prod Medical treatment
GB9517559D0 (en) 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
GB9607219D0 (en) 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
PL186541B1 (pl) 1996-04-12 2004-01-30 Janssen Pharmaceutica Nv Nowy związek, pochodna izoksazolidyny, kompozycjafarmaceutyczna, zastosowanie pochodnej izoksazolidyny i sposób wytwarzania pochodnej izoksazolidyny
EP0813873B1 (en) * 1996-06-19 2002-02-13 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
ID26861A (id) * 1998-05-22 2001-02-15 Lilly Co Eli Terapi gabungan untuk pengobatan depresi refaktori
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
NZ507981A (en) * 1998-05-29 2003-10-31 Lilly Co Eli Combination therapy for treatment of bipolar disorders
DE19827750C1 (de) * 1998-06-22 1999-07-29 Centeon Pharma Gmbh Verfahren zum Abtrennen von HIV aus einer Flüssigkeit
DE19900673A1 (de) * 1999-01-11 2000-07-13 Basf Ag Verwendung von Bindungspartnern für 5-HT5-Rezeptoren zur Behandlung neurodegenerativer und neuropsychiatrischer Störungen
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram

Also Published As

Publication number Publication date
HUP0203586A2 (hu) 2003-03-28
JP2003516326A (ja) 2003-05-13
CA2393470A1 (en) 2001-06-14
CZ20021961A3 (cs) 2002-11-13
IS6404A (is) 2002-05-31
DE60025398T2 (de) 2006-08-03
IS2227B (is) 2007-04-15
US20020103249A1 (en) 2002-08-01
WO2001041766A1 (en) 2001-06-14
MEP6208A (en) 2010-02-10
US20030032636A1 (en) 2003-02-13
NO20022657L (no) 2002-07-26
PL356402A1 (en) 2004-06-28
US20070105843A1 (en) 2007-05-10
AU1850801A (en) 2001-06-18
IL149994A0 (en) 2002-12-01
BG106895A (bg) 2003-04-30
NO20022657D0 (no) 2002-06-05
PT1237553E (pt) 2006-05-31
BR0016385A (pt) 2003-02-18
ZA200204391B (en) 2003-11-26
KR20020060987A (ko) 2002-07-19
TR200201512T2 (tr) 2002-09-23
MXPA02005613A (es) 2002-12-13
UA77650C2 (en) 2007-01-15
CN1433313A (zh) 2003-07-30
EP1237553B1 (en) 2006-01-04
EA200200649A1 (ru) 2002-12-26
EA006391B1 (ru) 2005-12-29
NZ545907A (en) 2007-07-27
AU1851101A (en) 2001-06-18
CY1105014T1 (el) 2009-11-04
DE60025398D1 (de) 2006-03-30
EP1237553A2 (en) 2002-09-11
CN101406465A (zh) 2009-04-15
HRP20020527A2 (en) 2004-12-31
CO5251409A1 (es) 2003-02-28
WO2001041701A3 (en) 2001-12-13
US20090176808A1 (en) 2009-07-09
KR100832026B1 (ko) 2008-05-23
ATE314849T1 (de) 2006-02-15
EP2036564A1 (en) 2009-03-18
SK7962002A3 (en) 2002-09-10
ES2255519T3 (es) 2006-07-01
HUP0203586A3 (en) 2005-02-28
DK1237553T3 (da) 2006-05-15
IL149994A (en) 2007-07-24
WO2001041701A2 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
WO2001041701A3 (en) The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist
AU1529402A (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
AR020345A1 (es) Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones.
DE60324544D1 (de) Muskarin antagonisten
MXPA05012812A (es) Compuestos, metodos y composiciones farmaceuticas para inhibir poli(adenosina-5'-difosfo-ribosa)polimerasa(parp).
MY133238A (en) Monoamine reuptake inhibitors for treatment for cns disorders
MY134568A (en) Cb2 receptor agonists
AU2003228770A8 (en) Substituted pyrazolopyrimidines
MY137480A (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
MXPA03009750A (es) Compuestos quimicos.
GB0111186D0 (en) Novel compounds
DE60206164D1 (de) Trisubstituierte-n-((1s)-1,2,3,4-tetrahydro-1-naphthalenyl) benzamide welche p2x3 und p2x2/3 enthaltende rezeptoren inhibieren
WO2003068207A3 (en) Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity
MY135916A (en) Use of certain affinity nmda antagonists as antidepressants
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
EP1254668A3 (en) Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
DE60201074D1 (en) Pyrazolopyridinderivate
EP1396267A3 (en) The combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist
BRPI0412268A (pt) compostos contendo um inibidor seletivo da recaptação de serotonina e antagonista de receptor 5-ht2a
BR0207716A (pt) Composto, formulação farmacêutica, e, método para a inibição de captação de norepinefrina e de serotonina em mamìferos
MY121063A (en) Use of nmda antagonists for treatment of irritable bowel syndrome
AU2001267421A1 (en) Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
EA200600101A1 (ru) Лечение депрессии и других аффективных расстройств
BR0206710A (pt) Composição limpadora sólida